ArticleFrontiers in pharmacology2025
Over the counter CBD products in Germany: an exploratory survey about consumption patterns and health related effects.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Regulation and Use of Cannabidiol in Croatia Compared with Selected European and International Models: From Consumer Products to Clinical Practice.Journal of clinical medicine · 2026Review
- Hemp (International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over-the-counter cannabidiol (CBD) products are showing substantial growth in marked share in recent years. However, the knowledge about health effects of these products is currently weak. In an explorative, retrospective online survey, the reasons for consumption, possible health-promoting or therapeutic effects, and adverse effects among CBD consumers in Germany were investigated. The anonymous questionnaire was accessible from 21 February 2023 to 20 June 2023. Participants (n = 208) were recruited mainly via social internet platforms. The study data was collected and managed using SoSci-Survey
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.